Render Target: STATIC
Render Timestamp: 2024-11-21T13:49:44.676Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:58:49.244
Product last modified at: 2024-11-04T22:15:08.338Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

MCT1/SLC16A1 (E7A2K) Rabbit mAb #76508

Filter:
  • WB
  • IHC
  • IF
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 43
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:50 - 1:200
    Immunofluorescence (Immunocytochemistry) 1:800 - 1:1600
    Flow Cytometry (Fixed/Permeabilized) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    MCT1/SLC16A1 (E7A2K) Rabbit mAb recognizes endogenous levels of total MCT1/SLC16A1 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly472 of human MCT1/SLC16A1 protein.

    Background

    MCT1, also known as MOT1, is a multi-pass transmembrane monocarboxylate transporter (MCT) protein, encoded by the gene SLC16A1 (1,2). MCT1 is reported to be expressed in multiple tissues and cell types, including erythrocytes, immune cells, and both cardiac and skeletal myocytes. The primary role of MCT1 is to facilitate proton-coupled transport of monocarboxylates (e.g., lactate, pyruvate, ketone bodies) across the plasma membrane in response to cellular metabolic demands (1). The regulation of monocarboxylate flux by MCT1 has been identified as a possible metabolic biomarker in various diseases, including neurodegenerative diseases, ischemia, and cancer (2-5). Inhibition of MCT1 has thus been proposed as a potential therapeutic treatment of cancer (5,6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.